Michel Wakselman

Title: Michel Wakselman: Innovator in Cyclopeptide and N-Aryl-Azetidinone Research

Introduction

Michel Wakselman is a notable inventor based in Paris, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of selective inhibitors for proteases. With a total of 2 patents, his work has implications for therapeutic applications.

Latest Patents

Wakselman's latest patents include innovative compounds that serve as selective inhibitors. One of his notable inventions is related to cyclopeptide derivatives that can be used as protease inhibitors. This invention complies with a specific formula where R¹ is a halogen atom, such as bromine, or a radical, while R² can be a hydrogen atom or an alkyl radical. Another significant patent involves N-aryl-azetidinones, which are described as active serine elastase inhibitors. These compounds are characterized by their irreversible and selective inhibition properties, making them valuable in therapeutic contexts.

Career Highlights

Throughout his career, Michel Wakselman has worked with esteemed organizations such as Scientifique and the Centre National de la Recherche Scientifique. His research has focused on developing compounds that can effectively target and inhibit specific enzymes, contributing to advancements in drug development.

Collaborations

Wakselman has collaborated with notable colleagues, including Roger Joyeau and Randa Kobaiter. These partnerships have facilitated the exchange of ideas and expertise, enhancing the quality and impact of his research.

Conclusion

Michel Wakselman's contributions to the field of medicinal chemistry through his innovative patents highlight his role as a significant inventor. His work on cyclopeptide derivatives and N-aryl-azetidinones showcases the potential for developing new therapeutic agents.